



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Knight, et al.

§

ART UNIT:

§

FILED: September 16, 2003

§

§

EXAMINER:

§

SERIAL NO.: 10/663,573

§

FOR: Small Particle Aerosol Liposomes

§

DOCKET:

For delivery of Anti-Cancer Drugs

§

D6030D/C/CIP

Commissioner of Patents

Attn: Customer Service Center

P.O. BOX 1450

Alexandria, VA 22313

**REQUEST FOR FILING RECEIPT CORRECTION AND  
CERTIFICATE OF MAILING UNDER 37 CFR 1.8**

Dear Sir:

Applicant hereby requests a correction to the filing receipt for the above-referenced patent application. In Domestic Priority Data, please correct U.S. Serial No. "09/969,674" to 09/969,374. In addition, please correct the filing date from "10/02/2001" to 10/01/2001. The corrections are noted in red on the enclosed copy.

I hereby certify under 37 CFR 1.8 that the following correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313. Please return the enclosed postcard acknowledging receipt of this correspondence.

Respectfully submitted,

DATE:

ADLER & ASSOCIATES

8011 Candle Lane

Houston, Texas 77071

713/270-5391

BADLER1@houston.rr.com

Benjamin Aaron Adler, Ph.D., J.D.

Registration No. 35,423

Counsel for Applicant



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/663,573	09/16/2003	1615	375	D6030D/C/CIP	10	19	2

CONFIRMATION NO. 2987

Benjamin Aaron Adler  
 ADLER & ASSOCIATES  
 8011 Candle Lane  
 Houston, TX 77071

## FILING RECEIPT



\*OC000000011461920\*

Date Mailed: 12/11/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

## Applicant(s)

J. Vernon Knight, Houston, TX;  
 Nadezhda Koshkina, Houston, TX;  
 Brian Gilbert, Houston, TX;  
 Claire F. Verschraegen, Residence Not Provided;

## Domestic Priority data as claimed by applicant

This application is a CIP of ~~09/969,674~~ ~~10/02/2001~~ \* *09/969,374 10/01/2001*  
 which is a CON of 09/353,496 07/15/1999 ABN  
 which is a DJV of 08/933,254 09/23/1997 PAT 6,090,407  
 (\*)Data provided by applicant is not consistent with PTO records.

## Foreign Applications

If Required, Foreign Filing License Granted: 12/09/2003

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\*

**Title**

Small particle liposome aerosols for delivery of anticancer drugs

**Preliminary Class**

424

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls; Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).